| Literature DB >> 20616983 |
Maryam M Asgari1, Jimmy T Efird, E Margaret Warton, Gary D Friedman.
Abstract
Recently, a population-based case-control study observed a 60% increased odds ratio (OR) for cutaneous squamous cell carcinoma (SCC) among women who had ever used oral contraceptives (OCs) compared with non users (95% confidence interval (CI) = 1.0-2.5). To further characterize the putative association between OC use and SCC risk, we conducted a nested case-control study using a large retrospective cohort of 111,521 Kaiser Permanente Northern California members. Multivariable conditional logistic regression was used to estimate ORs and CIs adjusting for known and hypothesized SCC risk factors. Pre-diagnostic OC use was associated with a statistically significant increased OR for SCC in univariate analysis (OR = 2.4, CI = 1.2-4.8), with borderline statistical significance in multivariable analysis (CI = 2.0, CI = 0.91-4.5). Given the high incidence of SCC in the general population and the prevalent use of OCs among women in the United States, there is a need for more large, carefully designed epidemiologic studies to determine whether the observed association between OC use and SCC can be replicated and to better understand the etiologic basis of an association if one exists.Entities:
Keywords: epidemiology; oral contraceptives; risk factors; squamous cell carcinoma
Mesh:
Substances:
Year: 2010 PMID: 20616983 PMCID: PMC2872290 DOI: 10.3390/ijerph7020427
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Conditional logistic regression models comparing cases and controls.*
| Marital status | ||||
| Never married | ||||
| Male | 20 (6) | 33 (3) | 1.0 Referent | 1.0 Referent |
| Female | 7 (4) | 26 (4) | 1.0 Referent | 1.0 Referent |
| Married | ||||
| Male | 237 (74) | 791 (78) | 0.62 (0.31–1.3) | 0.71 (0.33–1.5) |
| Female | 118 (61) | 402 (59) | 1.1 (0.45–2.8) | 1.5 (0.54–4.3) |
| Separated/divorced/widowed | ||||
| Male | 16 (5) | 65 (6) | 0.66 (0.27–1.7) | 0.77 (0.29–2.1) |
| Female | 43 (22) | 142 (21) | 1.3 (0.50–3.5) | 1.8 (0.61–5.5) |
| Education (years of college) | ||||
| High school or less | ||||
| Male | 130 (41) | 459 (45) | 1.0 Referent | 1.0 Referent |
| Female | 94 (48) | 368 (54) | 1.0 Referent | 1.0 Referent |
| Any college | ||||
| Male | 176 (55) | (47) | 1.4 (1.02–1.9) | 1.3 (0.95–1.8) |
| Female | 92 (47) | 262 (39) | 1.8 (1.2–2.6) | 1.9 (1.2–2.8) |
| Body Mass Index (kg/m2) | ||||
| <20 (underweight) | ||||
| Male | 5 (2) | 17 (2) | 0.64 (0.20–2.0) | 0.58 (0.16–2.1) |
| Female | 25 (13) | 60 (9) | 0.95 (0.55–1.6) | 1.0 (0.55–1.9) |
| 20–25 (healthy) | ||||
| Male | 157 (49) | 348 (34) | 1.0 Referent | 1.0 Referent |
| Female | 109 (56) | 303 (45) | 1.0 Referent | 1.0 Referent |
| ≥25 (overweight) | ||||
| Male | 150 (47) | 434 (43) | 0.78 (0.60–1.02) | 0.78 (0.59–1.04) |
| Female | 58 (30) | 169 (25) | 0.94 (0.63–1.4) | 1.1 (0.69–1.6) |
| Eye color (right) | ||||
| Brown | ||||
| Male | 72 (22) | 307 (30) | 1.0 Referent | 1.0 Referent |
| Female | 39 (20) | 218 (32) | 1.0 Referent | 1.0 Referent |
| Green | ||||
| Male | 6 (2) | 38 (4) | 0.73 (0.29–1.9) | 0.63 (0.23–1.8) |
| Female | 17 (9) | 36 (5) | 2.7 (1.3–5.5) | 2.6 (1.2–5.5) |
| Blue/gray | ||||
| Male | 184 (57) | 495 (49) | 1.6 (1.1–2.0) | 1.6 (1.1–2.2) |
| Female | 99 (51) | 322 (47) | 1.7 (1.1–2.6) | 1.9 (1.2–2.9) |
| Other | ||||
| Male | 59 (18) | 171 (17) | 1.6 (1.1–2.5) | 1.5 (0.98–2.4) |
| Female | 40 (21) | 103 (15) | 2.0 (1.2–3.5) | 2.2 (1.2–3.9) |
| Personal history of cancer | ||||
| No | ||||
| Male | 290 (90) | 975 (96) | 1.0 Referent | 1.0 Referent |
| Female | 167 (86) | 583 (86) | 1.0 Referent | 1.0 Referent |
| Yes | ||||
| Male | 31 (10) | 36 (4) | 2.8 (1.6–4.9) | 2.8 (1.5–5.0) |
| Female | 28 (14) | 96 (14) | 1.1 (0.69–1.8) | 0.93 (0.55–1.6) |
| Smoking status (cigarettes) | ||||
| Never | ||||
| Male | 123 (38) | 366 (36) | 1.0 Referent | 1.0 Referent |
| Female | 105 (54) | 397 (58) | 1.0 Referent | 1.0 Referent |
| Former | ||||
| Male | 105 (33) | 384 (38) | 0.90 (0.65–1.2) | 0.91 (0.64–1.3) |
| Female | 36 (18) | 104 (15) | 1.6 (0.99–2.6) | 1.6 (0.97–2.8) |
| Current | ||||
| Male | 93 (29) | 261 (26) | 1.0 (0.74–1.4) | 1.0 (0.71–1.5) |
| Female | 54 (28) | 178 (26) | 1.0 (0.69.1.6) | 1.0 (0.64–1.6) |
| Ultraviolet radiation | ||||
| No | ||||
| Male | 312 (97) | 1005 (99) | 1.0 Referent | 1.0 Referent |
| Female | 193 (99) | 675 (99) | 1.0 Referent | 1.0 Referent |
| Yes | ||||
| Male | 9 (3) | 6 (1) | 4.4 (1.5–13) | 5.0 (1.7–15) |
| Female | 2 (1) | 4 (1) | 3.0 (0.51–18) | 2.5 (0.34–20) |
| Leisure time activities (# hours/day) | ||||
| 0–1 | ||||
| Male | 32 (10) | 112 (11) | 1.0 Referent | 1.0 Referent |
| Female | 19 (10) | 89 (13) | 1.0 Referent | 1.0 Referent |
| 2–4 | ||||
| Male | 207 (64) | 651 (64) | 1.1 (0.71–1.8) | 1.3 (0.76–2.1) |
| Female | 121 (62) | 425 (63) | 1.4 (0.82–2.6) | 1.4 (0.76–2.7) |
| 5–7 | ||||
| Male | 37 (12) | 76 (8) | 1.6 (0.84–2.9) | 1.8 (0.92–3.6) |
| Female | 23 (12) | 46 (7) | 2.7 (1.2–5.8) | 2.7 (1.1–6.4) |
| >7 | ||||
| Male | 10 (3) | 15 (1) | 3.3 (1.1–9.5) | 3.8 (1.2–12) |
| Female | 2 (1) | 7 (1) | 1.4 (0.24–7.7) | 1.1 (0.18–6.7) |
| Exercise(# hours/day) | ||||
| 0–1 | ||||
| Male | 176 (55) | 504 (50) | 1.0 Referent | 1.0 Referent |
| Female | 100 (51) | 384 (57) | 1.0 Referent | 1.0 Referent |
| 2–4 | ||||
| Male | 93 (29) | 283 (28) | 0.89 (0.65–1.2) | 0.91 (0.65–1.3) |
| Female | 57 (29) | 150 (22) | 1.6 (1.1–2.4) | 1.5 (0.95–2.3) |
| 5–7 | ||||
| Male | 10 (3) | 41 (4) | 0.66 (0.30–1.4) | 0.67 (0.29–1.5) |
| Female | 7 (4) | 22 (3) | 1.5 (0.58–3.8 | 1.3 (0.44–3.7) |
| >7 | ||||
| Male | 6 (2) | 23 (2) | 0.86 (0.32–2.3) | 0.82 (0.28–2.4) |
| Female | 1 (1) | 11 (2) | 0.22 (0.03–1.8) | 0.15 (0.02–1.5) |
| Oral contraceptives | ||||
| No | 172 (88) | 638 (94) | 1.0 Referent | 1.0 Referent |
| Yes | 23 (12) | 41 (6) | 2.4 (1.2–4.8) | 2.0 (0.91–4.5) |
| Aspirin (# daily pills) | ||||
| ≤6 | ||||
| Male | 316 (98) | 994 (98) | 1.0 Referent | 1.0 Referent |
| Female | 191 (98) | 664 (98) | 1.0 Referent | 1.0 Referent |
| >6 | ||||
| Male | 5 (2) | 17 (2) | 1.1 (0.35–3.2) | 1.0 (0.31–3.3) |
| Female | 4 (2) | 15 (2) | 0.76 (0.20–2.9) | 0.69 (0.15–3.1) |
| Cortisone type medication | ||||
| No | ||||
| Male | 310 (97) | 965 (95) | 1.0 Referent | 1.0 Referent |
| Female | 185 (95) | 644 (95) | 1.0 Referent | 1.0 Referent |
| Yes | ||||
| Male | 11 (3) | 46 (5) | 0.80 (0.40–1.6) | 0.78 (0.36–1.7) |
| Female | 10 (5) | 35 (5) | 1.2 (0.53–2.6) | 1.1 (0.45–2.6 |
| Ultraviolet radiation | ||||
| No | ||||
| Male | 312 (97) | 1005 (99) | 1.0 Referent | 1.0 Referent |
| Female | 193 (99) | 675 (99) | 1.0 Referent | 1.0 Referent |
| Yes | ||||
| Male | 9 (3) | 6 (1) | 4.4 (1.5–13) | 5.0 (1.7–15) |
| Female | 2 (1) | 4 (1) | 3.0 (0.51–18) | 2.5 (0.34–19) |
| Dusts (asbestos, cement, or grain) | ||||
| No | ||||
| Male | 311 (97) | 942 (93) | 1.0 Referent | 1.0 Referent |
| Female | 195 (100) | 677 (100) | 1.0 Referent | 1.0 Referent |
| Yes | ||||
| Male | 10 (3) | 69 (7) | 0.41 (0.20–0.83) | 0.40 (0.19–0.87) |
| Female | 0 (0) | 2 (0) | --- | --- |
Controls individually matched by gender, postal zip code of residence at time of diagnosis, birth year within 2 years, and year of MHCQ within 5 years.
Adjusted for all other variables in table.
Unknown category not shown.
Defined as “Hobby, TV, etc.”
Defined as “Walking, sports, etc.”
Physician diagnosed.
Including Aspirin, Empirin, Anacin, or Bufferin.
Approximate usage on daily basis .
Used in the past year.
Often or daily around at place of work.
Women only.
Not computed due to zero referent cell.